The global pediatric medicines market is anticipated to grow at a significant CAGR of around 5% during the forecast years. Pediatric medicines are the branch of the healthcare industry tech deals with the treatment of various diseases in children. One of the key factors for the growth of the global pediatric medicines market is the increasing number of pediatric patients due to the increasing pediatric population around the world. Infants, children, and young adults coming under the pediatric population may suffer infections, fever, pain, and other problems that can be treated using pediatric medicine. In addition, several research and development activities in the field of pediatric medicines have also improved health care by providing improved pediatric medicines to patients.
Browse the full report description of “Global Pediatric Medicines Market Size, Share & Trend Analysis Report by Drug Type (Allergy and Respiratory Drugs, Cancer Therapies, Cardiovascular Drugs, and Gastrointestinal Drugs), By the Route of Administration (Oral, Topical, and Parenteral), Forecast (2022-2028)” at https://www.omrglobal.com/industry-reports/pediatric-medicines-market
According to the report published on UpToDate, Inc. in November 2021, atenolol can be used for the treatment of complicated infantile hemangiomas. Atenolol is a selective beta-1 blocker and equally effective as propranolol. Hemangiomas are a birthmark that is bright red in color and shows up after one or two weeks of birth. In the study, the medicine was used on randomized 400 infants with problematic hemangiomas and the conclusions were that antennal can be used as a treatment for problematic and complicated hemangiomas. Furthermore, in November 2021, the Center for Disease Control and Prevention (CDC) has updated the threshold for elevated blood lead in the children of the US. The blood lead level (BLL) has been lowered to 3.5 mcg/dl from the previous level of 5 mcg/dl. This was done to lessen the risk of neurocognitive deficits in infants and children aged below 6 years. These developments in pediatric medicines and increasing pediatric patients are expected to propel the growth of the global pediatric medicines market.
Market Coverage
• The market number available for – 2022-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By Drug Type
o By the Route of Administration
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- Abbvie Inc., Johnson & Johnson, Bayer AG, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., and Others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Pediatric Medicines Market Report Segment
By Drug Type
By the Route of Administration
Global Pediatric Medicines Market Report Segment by Region
North America
• The US
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/pediatric-medicines-market